Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

61.25 -0.06 (-0.10%)
Streaming Delayed Price Updated: 10:35 AM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Benzinga Pro's Top 5 Stocks To Watch For Monday, Jan. 31, 2022: NFLX, BB, IONS, NXPI, EA
Today's 5 Stock Ideas: Netflix (NFLX) - Shares up premarket. Citigroup upgraded the stock from Neutral to Buy and announced a $450 price target. Also, Co-CEO Reed Hastings... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Madrigal Pharmaceuticals (NASDAQ:MDGL) shares rose 14.9% to $64.8 during Monday's pre-market session. The market value of their outstanding shares is at $1.1... 
Via Benzinga
Ionis' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder
The FDA has granted orphan drug designation to Ionis Pharmaceuticals Inc's (NASDAQ: IONS) eplontersen, an investigational antisense medicine for... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
Where Ionis Pharmaceuticals Stands With Analysts
Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed ... 
Via Benzinga
Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years?
One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t... 
Via Benzinga
The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. Here are the key catalysts that can sway biotech stocks in the unfolding week. 
Via Talk Markets
The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. On the regulatory front, the Food And Drug Administration... 
Via Benzinga
Jim Cramer Shares His Thoughts On Canadian Pacific Railway, Royalty Pharma And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Canadian Pacific Railway Limited (NYSE: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2021
Upgrades According to Wells Fargo, the prior rating for Douglas Emmett Inc (NYSE: 
Via Benzinga
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers ACADIA Pharmaceuticals (NASDAQ:ACAD) stock rose 18.35% to $22.96 during Tuesday's pre-market session. The company's market cap stands at $3.6 billion.... 
Via Benzinga
Ionis, AstraZeneca Ink Licensing Pact For Eplontersen In Protein Misfolding Disorder
Ionis Pharmaceuticals Inc (NASDAQ: IONS) has entered into a strategic collaboration agreement with AstraZeneca Plc (NASDAQ: AZN) to develop and... 
Via Benzinga
Pfizer Posts Vupanorsen Data From Mid-Stage Cardiovascular Disease Trial
Pfizer Inc (NYSE: PFE) has provided an update on the Phase 2b study of vupanorsen, investigational antisense therapy for cardiovascular (CV) risk reduction and severe... 
Via Benzinga
How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022
Alnylam is working on a drug that could tackle transthyretin cardiomyopathy. 
Via Investor's Business Daily
Barron's Most Recent Picks And Pans: General Electric, Pfizer, Walt Disney And More
This weekend's Barron's cover story examines the revival of mall stocks. Other featured articles discuss why small-cap stocks are the next big thing and some energy... 
Via Benzinga
Ionis Pharmaceuticals, inc (IONS) Q3 2021 Earnings Call Transcript
IONS earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Why Ionis Pharmaceuticals Stock Is Down 13% This Week
An experimental treatment for amyotrophic lateral sclerosis missed the mark in a phase 3 trial. 
Via The Motley Fool
46 Biggest Movers From Yesterday
Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial... 
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.... 
Via Benzinga
Ionis Stock Collapses On Another 'Misstep' As Biogen-Partnered ALS Drug Flops
Biogen and Ionis' approach to Lou Gehrig's disease missed its key goal. 
Via Investor's Business Daily
Biogen's Antisense Candidate Flunks In Late-Stage Neurodegenerative Disorder Trial
Biogen Inc (NASDAQ: BIIB) has announced topline results from its Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense drug for superoxide... 
Via Benzinga
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
PTC Therapeutics' Waylivra Scores Approval In Brazil For Genetic Disorder
The Brazilian Health Regulatory Agency has approved PTC Therapeutics Inc's (NASDAQ: PTCT) Waylivra (volanesorsen) as the first treatment for familial... 
Via Benzinga
Ionis Pharmaceuticals, inc (IONS) Q2 2021 Earnings Call Transcript
IONS earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
After Aduhelm Win, Biogen Touts Encouraging Data From Second Alzheimer's Candidate
Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have announced topline data from a Phase 1b study of BIIB080/IONIS-MAPTRx in mild... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.